Literature DB >> 19322918

Risk of contrast-induced nephropathy in hospitalized patients with cirrhosis.

Nilesh Lodhia1, Michael Kader, Thalia Mayes, Parvez Mantry, Benedict Maliakkal.   

Abstract

AIM: To evaluate the incidence of contrast-induced nephropathy (CIN) in cirrhotic patients and to identify risk factors for the development of CIN.
METHODS: We performed a retrospective review of 216 consecutive patients with cirrhosis who underwent computed tomography (CT) with intravenous contrast at the University of Rochester between the years 2000-2005. We retrospectively examined factors associated with a high risk for CIN, defined as a decrease in creatinine clearance of 25% or greater within one week after receiving contrast.
RESULTS: Twenty-five percent of our patients developed CIN, and 74% of these patients had ascites seen on CT. Of the 75% of patients who did not develop CIN, only 46% had ascites. The presence of ascites was a significant risk factor for the development of CIN (P = 0.0009, OR 3.38, 95% CI 1.55-7.34) in multivariate analysis. Patient age, serum sodium, Model for End-stage Liver Disease score, diuretic use, and the presence of diabetes were not found to be significant risk factors for the development of CIN. Of the patients who developed CIN, 11% developed chronic renal insufficiency, defined as a creatinine clearance less than baseline for 6 wk.
CONCLUSION: Our results suggest that in hospitalized cirrhotic patients, especially those with ascites, the risk of CIN is substantial.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19322918      PMCID: PMC2665139          DOI: 10.3748/wjg.15.1459

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  49 in total

1.  A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity.

Authors:  Hariprasad S Trivedi; Harold Moore; Samer Nasr; Kul Aggarwal; Alok Agrawal; Punit Goel; John Hewett
Journal:  Nephron Clin Pract       Date:  2003-01

2.  Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty.

Authors:  Christian Mueller; Gerd Buerkle; Heinz J Buettner; Jens Petersen; André P Perruchoud; Urs Eriksson; Stephan Marsch; Helmut Roskamm
Journal:  Arch Intern Med       Date:  2002-02-11

Review 3.  Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia.

Authors:  S N Heyman; J Reichman; M Brezis
Journal:  Invest Radiol       Date:  1999-11       Impact factor: 6.016

4.  The risk of radiocontrast nephropathy in patients with cirrhosis.

Authors:  M Najjar; A Hamad; M Salameh; A Agarwal; D A Feinfeld
Journal:  Ren Fail       Date:  2002-01       Impact factor: 2.606

5.  Mortality associated with nephropathy after radiographic contrast exposure.

Authors:  Aaron M From; Brian J Bartholmai; Amy W Williams; Stephen S Cha; Furman S McDonald
Journal:  Mayo Clin Proc       Date:  2008-10       Impact factor: 7.616

6.  Effects of contrast media on renal function in patients with cirrhosis: a prospective study.

Authors:  Mònica Guevara; Glòria Fernández-Esparrach; Carlo Alessandria; Aldo Torre; Carlos Terra; Xavier Montañà; Carlos Piera; Maria Luisa Alvarez; Wladimiro Jiménez; Pere Ginès; Vicente Arroyo
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

7.  A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation.

Authors:  Roxana Mehran; Eve D Aymong; Eugenia Nikolsky; Zoran Lasic; Ioannis Iakovou; Martin Fahy; Gary S Mintz; Alexandra J Lansky; Jeffrey W Moses; Gregg W Stone; Martin B Leon; George Dangas
Journal:  J Am Coll Cardiol       Date:  2004-10-06       Impact factor: 24.094

Review 8.  Acute renal failure in patients with cirrhosis: perspectives in the age of MELD.

Authors:  Richard Moreau; Didier Lebrec
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

9.  Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial.

Authors:  Gregory J Merten; W Patrick Burgess; Lee V Gray; Jeremiah H Holleman; Timothy S Roush; Glen J Kowalchuk; Robert M Bersin; Arl Van Moore; Charles A Simonton; Robert A Rittase; H James Norton; Thomas P Kennedy
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

10.  Role of serum creatinine and prognostic scoring systems in assessing hospital mortality in critically ill cirrhotic patients with upper gastrointestinal bleeding.

Authors:  Yung-Chang Chen; Ming-Hung Tsai; Ching-Wei Hsu; Yu-Pin Ho; Jau-Min Lien; Ming-Yang Chang; Ji-Tseng Fang; Chiu-Ching Huang; Pan-Chi Chen
Journal:  J Nephrol       Date:  2003 Jul-Aug       Impact factor: 3.902

View more
  13 in total

Review 1.  Treatment and management of ascites and hepatorenal syndrome: an update.

Authors:  Kurt Lenz; Robert Buder; Lisbeth Kapun; Martin Voglmayr
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

Review 2.  [Renal insufficiency in patients with hepatic insufficiency].

Authors:  K Lenz; M Binder; R Buder; A Gruber; B Gutschreiter; M Voglmayr
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-26       Impact factor: 0.840

Review 3.  Surgery in a patient with liver disease.

Authors:  Rakesh Rai; Sanjay Nagral; Aabha Nagral
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

4.  Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study.

Authors:  Bo-Ching Lee; Kao-Lang Liu; Cheng-Li Lin; Chia-Hung Kao
Journal:  Eur Radiol       Date:  2017-06-07       Impact factor: 5.315

Review 5.  The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists.

Authors:  Ponni V Perumalswami; Thomas D Schiano
Journal:  Dig Dis Sci       Date:  2011-03-18       Impact factor: 3.199

6.  Harms of hepatocellular carcinoma surveillance.

Authors:  Jan Petrasek; Amit G Singal; Nicole E Rich
Journal:  Curr Hepatol Rep       Date:  2019-10-15

7.  Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography.

Authors:  Seok-In Hong; Shin Ahn; Yoon-Seon Lee; Won Young Kim; Kyung Soo Lim; Jae Ho Lee; Jae-Lyun Lee
Journal:  Support Care Cancer       Date:  2015-08-04       Impact factor: 3.603

Review 8.  INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease.

Authors:  Anil Arora; Ashish Kumar; Narayan Prasad; Ajay Duseja; Subrat K Acharya; Sanjay K Agarwal; Rakesh Aggarwal; Anil C Anand; Anil K Bhalla; Narendra S Choudhary; Yogesh K Chawla; Radha K Dhiman; Vinod K Dixit; Natarajan Gopalakrishnan; Ashwani Gupta; Umapati N Hegde; Sanjiv Jasuja; Vivek Jha; Vijay Kher; Ajay Kumar; Kaushal Madan; Rakhi Maiwall; Rajendra P Mathur; Suman L Nayak; Gaurav Pandey; Rajendra Pandey; Pankaj Puri; Ramesh R Rai; Sree B Raju; Devinder S Rana; Padaki N Rao; Manish Rathi; Vivek A Saraswat; Sanjiv Saxena; Praveen Sharma; Shivaram P Singh; Ashwani K Singal; Arvinder S Soin; Sunil Taneja; Santosh Varughese
Journal:  J Clin Exp Hepatol       Date:  2020-10-09

9.  Intravenous albumin for the prevention of contrast-induced nephropathy in patients with liver cirrhosis and chronic kidney disease undergoing contrast-enhanced CT.

Authors:  Heejung Choi; Yoonjung Kim; Soo Min Kim; Junam Shin; Hye Ryoun Jang; Jung Eun Lee; Wooseong Huh; Yoon-Goo Kim; Ha Young Oh; Dae Joong Kim
Journal:  Kidney Res Clin Pract       Date:  2012-04-23

10.  Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography.

Authors:  Roberto Filomia; Sergio Maimone; Gaia Caccamo; Carlo Saitta; Luca Visconti; Angela Alibrandi; Simona Caloggero; Antonio Bottari; Maria Stella Franzè; Carmine Gabriele Gambino; Tindaro Lembo; Giovanni Oliva; Irene Cacciola; Giovanni Raimondo; Giovanni Squadrito
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.